Controversy over two new drugs for Alzheimer's disease

Published On:

Context

Two newly developed drugs, lecane man and donanimhaber, have emerged as promising treatments for Alzheimer's disease, a neurodegenerative disorder that affects millions of people worldwide.

While these drugs represent progress in slowing cognitive decline, they have also sparked significant debate within the medical community.

Why in the news?

These Alzheimer's drugs are in the spotlight because of ongoing controversy about their effectiveness and the impact they may have on patients and their families. Some experts view the drugs as a breakthrough, while others argue that they offer false hope.

Background

Alzheimer's is the most common form of dementia, causing memory loss and cognitive decline in millions of people. For decades, researchers have been looking for effective treatments to slow the disease's progression, but many previous medications have failed, leaving a lack of reliable options for patients.

Which drugs became the subject of controversy?

At the center of the debate are 2 drugs -

Lecanemab, sold as Lecambi.

Donanimhaber, sold as Kisunla.

Lecanemab was developed by U.S. pharmaceutical companies Biogen and Eisai, while Eli Lilly produced donanimhaber. Both drugs are intended to slow the early progression of Alzheimer's disease.

Critics raised concerns

Critics, such as Rob Howard, a professor of geriatric psychiatry at University College London, argue that these drugs are being used to create "false and unrealistic expectations" for Alzheimer's patients and their families.

They believe the benefits of the drugs have been exaggerated, leading to controversy over their approval.

Conflicting views on effectiveness

The medical community is divided. Supporters, including British biologist John Hardy, see these drugs as the first real breakthrough after decades of research, claiming they represent a turning point in the treatment of Alzheimer's. However, critics are skeptical about their overall effectiveness and cost-effectiveness.

Limited effect on cognitive decline

Although both lecanemab and donanemab have been found to be able to reduce cognitive decline by about 30% in patients in the early stages of Alzheimer's, this improvement is thought to be limited.

Despite being the most effective treatments to date, the modest results fuel ongoing debate about their real value.

Conclusion

Lecanemab and donanemab are a step forward in the treatment of Alzheimer's but the controversy surrounding them highlights the challenges of striking a balance between hope and realism.

The debate reflects differing views on whether the potential benefits justify the high costs and high expectations.

Way forward

Further studies and long-term clinical trials are necessary to better understand the full effects of these drugs.

For now, patients and doctors should carefully evaluate the pros and cons, while continued research should aim to improve treatment options for Alzheimer's and strive for even more significant breakthroughs.